Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroid
via Wikipedia infobox
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally (swallowed by mouth).
Common side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).